 MENLO PARK, Calif., Dec. 09, 2020 GLOBE NEWSWIRE -- CohBar, Inc. NASDAQ: CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced new preclinical data confirming the efficacy of its apelin agonist peptides in a preclinical model of acute respiratory distress syndrome ARDS. The company expects the apelin agonists to have potential to treat COVID-19 associated ARDS as well as ARDS patients in general, of which there are approximately three million globally. 